VANCOUVER, BC — January 13, 2026 — Leads & Copy — VVT Med Inc., a developer of minimally invasive solutions for venous disease treatment, has announced that a procedure fee for ScleroSafe® treatments has been accepted in South Korea, marking progress toward commercial market penetration.
The acceptance of a procedure fee in South Korea is a crucial step that typically follows regulatory approval, reflecting clinical validation and professional consensus. It allows approved procedures to be performed within the national healthcare system under an established procedural framework.
This achievement follows a structured market-entry process in South Korea that began in 2022 when VVT Med executed a distribution agreement, establishing a local commercial framework. In 2024, ScleroSafe received regulatory approval from the Korean Ministry of Food and Drug Safety (MFDS), enabling its clinical use in the country. The Korean Phlebology Society issued a supportive opinion letter in 2025, highlighting ScleroSafe’s clinical and economic value. Subsequently, in December 2025, the procedure fee was accepted, allowing physicians to integrate the treatment into routine clinical practice.
Supporting these milestones is a distribution agreement in South Korea valued at approximately CAD 2.6 million.
Erez Tetro, CEO of VVT Med, stated that with the distribution framework in place since 2022, MFDS approval in 2024, and now the acceptance of a procedure fee, the key building blocks for meaningful market entry have been completed. He added that South Korea is a sophisticated medical market, and this milestone positions ScleroSafe for scalable clinical adoption.
ScleroSafe is positioned for structured market penetration in South Korea starting in 2026, supported by physician education initiatives, local distribution capabilities, and growing clinical awareness of non-thermal, minimally invasive venous treatments.
In other company news, shareholders approved the adoption of an omnibus equity incentive plan at the Company’s Annual General and Special Meeting of Shareholders held on December 12, 2025. The Omnibus Plan permits the grant of options equal to up to 10% of the Company’s issued and outstanding common shares from time to time, along with 6,683,360 common shares available for issuance pursuant to restricted share units, deferred share units, and performance share units. The Omnibus Plan remains subject to final approval from the TSX Venture Exchange.
The Company has granted 400,000 Options to I3 Capital Group Ltd. in connection with an investor relations agreement. Each Option is exercisable at a price of $0.34 for one common share of the Company for two years from the date of grant and are being issued under the terms of the Company’s Omnibus Plan. The Options, and any Common Shares issued upon exercise of the Options, are subject to a four-month and one-day resale restriction from the date of grant under applicable securities laws and the policies of the TSX Venture Exchange. The Options are subject to a 12‑month vesting schedule, with 25% of the Options vesting every three months following the date of grant.
About VVT Med Inc.
VVT Medical develops, manufactures, and distributes minimally invasive solutions for the treatment of vein diseases. VVT’s FDA-cleared and CE-marked catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures. VVT’s solutions address a range of vein diameters, treating both the medical and aesthetic aspects of vein disease.
About I3 Capital
I3 offers investor relations, corporate finance, M&A and equity research services for innovative, high-growth companies that are listed or seeking to list on North American securities exchanges.
Contact:
Erez Tetro, CEO of VVT Med.
Source: VVT Med Inc.
